<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mes</journal-id><journal-title-group><journal-title xml:lang="ru">Экстремальная биомедицина</journal-title><trans-title-group xml:lang="en"><trans-title>Extreme Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">3033-8964</issn><issn pub-type="epub">3033-8972</issn><publisher><publisher-name>Centre for Strategic Planning of the Federal Medical and Biological Agency</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.47183/mes.2025-284</article-id><article-id custom-type="elpub" pub-id-type="custom">mes-284</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКАЯ МЕДИЦИНА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL MEDICINE</subject></subj-group></article-categories><title-group><article-title>Болезнь Крона у ребенка с редким первичным иммунодефицитным состоянием: особенности консервативной и хирургической тактики</article-title><trans-title-group xml:lang="en"><trans-title>Crohn’s disease complicating a rare primary immunodeficiency in a pediatric patient: challenges in medical and surgical decision-making</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0001-5863-1556</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Алиева</surname><given-names>Э. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Alieva</surname><given-names>E. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Алиева Эльмира Ибрагимовна, д-р мед. наук</p><p>Москва</p></bio><bio xml:lang="en"><p>Elmira I. Alieva, Dr. Sci. (Med.)</p><p>Moscow</p></bio><email xlink:type="simple">el-alieva@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8514-3080</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Щербакова</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Shcherbakova</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Щербакова Ольга Вячеславовна, д-р мед. наук</p><p>Москва</p></bio><bio xml:lang="en"><p>Olga V. Shcherbakova, Dr. Sci. (Med.)</p><p>Moscow</p></bio><email xlink:type="simple">olga-03@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9717-5872</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зябкин</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Zyabkin</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Зябкин Илья Владимирович, д-р мед. наук</p><p>Москва</p></bio><bio xml:lang="en"><p>Ilya V. Zyabkin, Dr. Sci. (Med.)</p><p>Moscow</p></bio><email xlink:type="simple">ZyabkinIV@kidsfmba.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральный научно-клинический центр детей и подростков Федерального медико-биологического агентства</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Federal Scientific and Clinical Center for Children and Adolescents</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>08</day><month>09</month><year>2025</year></pub-date><volume>27</volume><issue>3</issue><fpage>410</fpage><lpage>416</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Алиева Э.И., Щербакова О.В., Зябкин И.В., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Алиева Э.И., Щербакова О.В., Зябкин И.В.</copyright-holder><copyright-holder xml:lang="en">Alieva E.I., Shcherbakova O.V., Zyabkin I.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.extrememedicine.ru/jour/article/view/284">https://www.extrememedicine.ru/jour/article/view/284</self-uri><abstract><sec><title>Введение</title><p>Введение. Первичные иммунодефицитные состояния (ПИДС) — это группа врожденных заболеваний, вызванных генетическими дефектами и обусловливающих разнообразные фенотипические проявления. Классические воспалительные заболевания кишечника (ВЗК) в большинстве случаев являются многофакторными патологиями, когда сочетаются генетическая предрасположенность, изменения кишечной микрофлоры и неблагоприятное влияние окружающей среды. Очень раннее начало ВЗК, с дебютом болезни в возрасте до 6 лет, составляет 3–15% всех детских воспалительных заболеваний кишечника. Именно для этой группы характерна моногенная этиология, протекающая в рамках ПИДС с гастроинтестинальным фенотипом и связанная с мутацией в конкретном гене.</p><p>Описание клинического случая. Представлен клинический случай моногенной болезни Крона у ребенка с Х-сцепленным лимфопролиферативным синдромом 2-го типа с демонстрацией многоэтапного командного подхода. Для достижения стойкой ремиссии, помимо подбора консервативной терапии, потребовалось проведение повторных хирургических вмешательств и повторных трансплантаций гемопоэтических стволовых клеток. Индивидуальный подход и планирование лечебной стратегии позволили достичь положительного результата лечения.</p></sec><sec><title>Выводы</title><p>Выводы. Очень важно у детей раннего возраста с атипичным течением воспалительного заболевания кишечника и рефрактерностью к стандартной терапии дифференцировать моногенные формы ВЗК. Такие пациенты требуют пристального внимания, динамического наблюдения, мультидисциплинарного подхода с альянсом гастроэнтеролога, иммунолога и хирурга.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction. Primary immunodeficiency disorders (PID) are a group of congenital diseases caused by genetic defects that lead to diverse phenotypic manifestations. Classic inflammatory bowel diseases (IBD) are typically multifactorial pathologies, combining genetic predisposition, gut microbiota alterations, and adverse environmental influences. Very early-onset IBD (VEO-IBD), defined as a disease presenting before six years of age, accounts for 3–15% of all pediatric IBD. This subgroup is particularly characterized by monogenic etiology, associated with gastrointestinal phenotype PID and with causative mutations in specific genes.</p></sec><sec><title>Case report</title><p>Case report. We present a clinical case of monogenic Crohn’s disease in a child with X-linked lymphoproliferative syndrome type 2 (XLP-2), treated using a multi-stage team approach. To achieve sustained remission, in addition to selecting conservative therapy, repeated surgical interventions and repeated hematopoietic stem cell transplantations were required. An individualized approach and treatment strategy planning enabled a positive treatment outcome.</p></sec><sec><title>Conclusions</title><p>Conclusions. In young children with the presence of atypical IBD and refractoriness to standard therapy, it is crucial to differentiate monogenic forms of IBD. Such patients require close monitoring, dynamic follow-up, and a multidisciplinary approach involving collaboration between gastroenterologists, immunologists, and surgeons.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>болезнь Крона</kwd><kwd>первичное иммунодефицитное состояние</kwd><kwd>Х-сцепленный лимфопролиферативный синдром</kwd><kwd>дети</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Crohn’s disease</kwd><kwd>primary immunodeficiency</kwd><kwd>X-linked lymphoproliferative syndrome</kwd><kwd>children</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Yu JE, Orange JS, Demirdag YY. New primary immunodeficiency diseases: context and future. Current Opinion in Pediatrics. 2018;30(6):806–20. https://doi.org/10.1097/MOP.0000000000000699</mixed-citation><mixed-citation xml:lang="en">Yu JE, Orange JS, Demirdag YY. New primary immunodeficiency diseases: context and future. Current Opinion in Pediatrics. 2018;30(6):806–20. https://doi.org/10.1097/MOP.0000000000000699</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Bousfiha A, Moundir A, Tangye SG, Picard C, Jeddane L, Al-Herz W, et al. The 2022 Update of IUIS Phenotypical Classification for Human Inborn Errors of Immunity. Journal of Clinical Immunology. 2022;42(7):1508–20. https://doi.org/10.1007/s10875-022-01352-z</mixed-citation><mixed-citation xml:lang="en">Bousfiha A, Moundir A, Tangye SG, Picard C, Jeddane L, Al-Herz W, et al. The 2022 Update of IUIS Phenotypical Classification for Human Inborn Errors of Immunity. Journal of Clinical Immunology. 2022;42(7):1508–20. https://doi.org/10.1007/s10875-022-01352-z</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Tangye SG, Al-Herz W, Bousfiha A, Cunningham-Rundles C, Franco JL, Holland SM, et al. Human inborn errors of immunity: 2022 update on the classification from the International Union of Immunological Societies Expert Committee. Journal of Clinical Immunology. 2022;42(7):1473–507. https://doi.org/10.1007/s10875-022-01289-3</mixed-citation><mixed-citation xml:lang="en">Tangye SG, Al-Herz W, Bousfiha A, Cunningham-Rundles C, Franco JL, Holland SM, et al. Human inborn errors of immunity: 2022 update on the classification from the International Union of Immunological Societies Expert Committee. Journal of Clinical Immunology. 2022;42(7):1473–507. https://doi.org/10.1007/s10875-022-01289-3</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Uhlig HH, Charbit-Henrion F, Kotlarz D, Shouval DS, Schwerd T, Strisciuglio C, et al. Clinical genomics for the diagnosis of monogenic forms of inflammatory bowel Disease: A position paper from the Paediatric IBD Porto Group of European Society of Paediatric Gastroenterology, Hepatology and Nutrition. Journal of Pediatric Gastroenterology and Nutrition. 2021;72(3):456–73. https://doi.org/10.1097/MPG.0000000000003017</mixed-citation><mixed-citation xml:lang="en">Uhlig HH, Charbit-Henrion F, Kotlarz D, Shouval DS, Schwerd T, Strisciuglio C, et al. Clinical genomics for the diagnosis of monogenic forms of inflammatory bowel Disease: A position paper from the Paediatric IBD Porto Group of European Society of Paediatric Gastroenterology, Hepatology and Nutrition. Journal of Pediatric Gastroenterology and Nutrition. 2021;72(3):456–73. https://doi.org/10.1097/MPG.0000000000003017</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Щиголева АЕ, Шумилов ПВ, Суспицын ЕН. Роль таргетного секвенирования в диагностике воспалительных заболеваний кишечника с очень ранним началом. Вопросы Детской Диетологии. 2020;18(1):28–34. https://doi.org/10.20953/1727-5784-2020-1-28-34</mixed-citation><mixed-citation xml:lang="en">Shchigoleva АЕ, Shumilov PV, Suspitsin ЕN. The role of targeted sequencing in diagnosis of very-early-onset inflammatory bowel disease. Pediatric Nutrition. 2020;18(1):28–34 (In Russ.). https://doi.org/10.20953/1727-5784-2020-1-28-34</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Tegtmeyer D, Seidl M, Gerner P, Baumann U, Klemann C. Inflammatory bowel disease caused by primary immunodeficiencies — Clinical presentations, review of literature, and proposal of a rational diagnostic algorithm. Pediatric Allergy and Immunology. 2017;28(5):412–29. https://doi.org/10.1111/pai.12734</mixed-citation><mixed-citation xml:lang="en">Tegtmeyer D, Seidl M, Gerner P, Baumann U, Klemann C. Inflammatory bowel disease caused by primary immunodeficiencies — Clinical presentations, review of literature, and proposal of a rational diagnostic algorithm. Pediatric Allergy and Immunology. 2017;28(5):412–29. https://doi.org/10.1111/pai.12734</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Щербина АЮ. Маски первичных иммунодефицитных состояний: проблемы диагностики и терапии. Российский Журнал Детской Гематологии и Онкологии. 2016;3(1):52–8. https://doi.org/10.17650/2311-1267-2016-3-1-52-58</mixed-citation><mixed-citation xml:lang="en">Shcherbina AYu. Masks of primary immunodeficiency disorders: diagnostic and therapeutic problems. Russian Journal of Pediatric Hematology and Oncology. 2016;3(1):52–8 (In Russ.). https://doi.org/10.17650/2311-1267-2016-3-1-52-58</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Sun S, Ye Z, Zheng S, Chen G, Qian X, Dong K, et al. Surgical treatment of monogenic infammatory bowel disease: A single clinical center experience. Journal of Pediatric Surgery. 2019;54(10):2155–61. https://doi.org/10.1016/j.jpedsurg.2019.02.013</mixed-citation><mixed-citation xml:lang="en">Sun S, Ye Z, Zheng S, Chen G, Qian X, Dong K, et al. Surgical treatment of monogenic infammatory bowel disease: A single clinical center experience. Journal of Pediatric Surgery. 2019;54(10):2155–61. https://doi.org/10.1016/j.jpedsurg.2019.02.013</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Kelsen JR, Sullivan KE, Rabizadeh S, Singh N, Snapper S, Elkadri A, et al. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition position paper on the evaluation and management for patients with very early-onset inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition. 2020;70(3):389–403. https://doi.org/10.1097/MPG.0000000000002567</mixed-citation><mixed-citation xml:lang="en">Kelsen JR, Sullivan KE, Rabizadeh S, Singh N, Snapper S, Elkadri A, et al. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition position paper on the evaluation and management for patients with very early-onset inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition. 2020;70(3):389–403. https://doi.org/10.1097/MPG.0000000000002567</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Bramuzzo M, Arrigo S, Romano C, Filardi MC, Lionetti P, Agrusti A, et al. Efficacy and safety of infliximab in very early onset inflammatory bowel disease: a national comparative retrospective study. United European Gastroenterology Journal. 2019;7(6):759–66. https://doi.org/10.1177/2050640619847592</mixed-citation><mixed-citation xml:lang="en">Bramuzzo M, Arrigo S, Romano C, Filardi MC, Lionetti P, Agrusti A, et al. Efficacy and safety of infliximab in very early onset inflammatory bowel disease: a national comparative retrospective study. United European Gastroenterology Journal. 2019;7(6):759–66. https://doi.org/10.1177/2050640619847592</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Ouahed J, Spencer E, Kotlarz D, Shouval DS, Kowalik M, Peng K, et al. Very early onset inflammatory bowel disease: A clinical approach with a focus on the role of genetics and underlying immune deficiencies. Inflammatory Bowel Diseases. 2020;26(6):820–42. https://doi.org/10.1093/ibd/izz259</mixed-citation><mixed-citation xml:lang="en">Ouahed J, Spencer E, Kotlarz D, Shouval DS, Kowalik M, Peng K, et al. Very early onset inflammatory bowel disease: A clinical approach with a focus on the role of genetics and underlying immune deficiencies. Inflammatory Bowel Diseases. 2020;26(6):820–42. https://doi.org/10.1093/ibd/izz259</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Балашов ДН, Роппельт АА, Румянцев АГ, Щербина АЮ. Первичный иммунодефицит — Х-сцепленный лимфопролиферативный синдром. Федеральные клинические рекомендации, 2020 г. Российский Аллергологический Журнал. 2019;16(4):66–77. https://doi.org/10.36691/RAJ.2020.16.4.008</mixed-citation><mixed-citation xml:lang="en">Balashov DN, Roppelt AA, Rumjantsev AG, Shcherbina AU. Х-linked lymphoproliferative syndrome. Federal clinical recommendations, 2020. Russian Journal of Allergology. 2019;16(4):66–77 (In Russ.). https://doi.org/10.36691/RAJ.2020.16.4.008</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Aguilar C, Latour S. X-linked inhibitor of apoptosis protein deficiency: more than an X-linked lymphoproliferative syndrome. Journal of Clinical Immunology. 2015;35(4):331–8. https://doi.org/10.1007/s10875-015-0141-9</mixed-citation><mixed-citation xml:lang="en">Aguilar C, Latour S. X-linked inhibitor of apoptosis protein deficiency: more than an X-linked lymphoproliferative syndrome. Journal of Clinical Immunology. 2015;35(4):331–8. https://doi.org/10.1007/s10875-015-0141-9</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Maxwell EC, Dawany N, Baldassano RN, Mamula P, Mattei P, Albenberg L, et al. Diverting ileostomy for the treatment of severe, refractory, pediatric inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition. 2017;65(3):299–305. https://doi.org/10.1097/MPG.0000000000001498</mixed-citation><mixed-citation xml:lang="en">Maxwell EC, Dawany N, Baldassano RN, Mamula P, Mattei P, Albenberg L, et al. Diverting ileostomy for the treatment of severe, refractory, pediatric inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition. 2017;65(3):299–305. https://doi.org/10.1097/MPG.0000000000001498</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Xu X, Zhou Y, Tan Z, Huang Y, Dong K, Gu Y, et al. Risk factors for stoma and incision complications of enterostomy in children with very early-onset inflammatory bowel disease: a prospective cohort study. European Journal of Pediatrics. 2025;184(2):146–70. https://doi.org/10.1007/s00431-024-05952-2</mixed-citation><mixed-citation xml:lang="en">Xu X, Zhou Y, Tan Z, Huang Y, Dong K, Gu Y, et al. Risk factors for stoma and incision complications of enterostomy in children with very early-onset inflammatory bowel disease: a prospective cohort study. European Journal of Pediatrics. 2025;184(2):146–70. https://doi.org/10.1007/s00431-024-05952-2</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
